Qyuns Therapeutics' (HKG:2509) phase 3 clinical study of its QX002N injection reached its primary endpoint showing better efficacy, safety, and tolerance in patients with moderate-to-severe active ankylosing spondylitis, a Monday bourse filing said.

The study showed the injection to have much higher efficacy than its market counterparts while its safety study revealed injection's treatment-emergent adverse events in grades 1 and 2.

The drug's incidence of adverse event rating was comparable to that of marketed drugs in the same class, with no new safety signals identified, according to the filing.

QX002N is a high-affinity monoclonal antibody and targets the IL-17A which is a key player in the pathological mechanism of various autoimmune diseases.

The injection is for the treatment of the chronic progressive inflammatory disease of the spinal joints, Ankylosing Spondylitis.

The disease causes inflammation of the spinal joints, resulting in reduced flexibility of the joints and stiffness in the spine over time.